No need to set it up to fail, selling branded Imodium for $1200 a clip is enough to make that team fail... “but doc it works on a different receptor!!!” They don’t care dummy.
That may be the single worst drug that has ever been shoved down Dr.'s mouths. The begging for 4-5 Rx's a week is laughable....NASH drug on life support good luck GI division... the future is bright
The company simply has different motivations. Trim the high payrolls, folks earning six figures in Woman's Health, CF & LTC, Eye Care, Neurology. Consolidate into leaner business unit's and larger PODs as you can hire 2 newbies for the price of one person who's delivered results for years. Want proof, at your next POA look at the average age and experience of your "specialty rep".They'll have a year or 2 of pharmaceutical experience. GI is set to fail. NASH drug delivering mixed result and the other drugs are 3 to 4 years away from a FDUCA date if the company is lucky. Viberzi releases too high in the HI track and needs reformulation to gain greater acceptance. Wall Street won't wait. When Nameda XR goes generic there will be another restructuring shortly thereafter and you'll see more senior level reps get fired across multiple divisions.Top performance is no guarantee for safety as that's not what's important to the Board right now. All the while managers and other forest born folks get promotions.
